US-based biopharma leader Bristol Myers Squibb is solidifying its leadership in hematology with compelling new data on multiple lymphoma therapies, presented at the 67th American Society of Hematology (ASH) Annual Meeting.
Highlights include updates on the company’s targeted protein degradation pipeline, first-in-class investigational agents golcadomide and BMS-986458, and long-term results for Breyanzi (lisocabtagene maraleucel; liso-cel), the CD19-directed CAR T cell therapy.
“The data presented at ASH represent a significant step forward in our pursuit of transformative outcomes for patients with lymphoma, who urgently need more effective and durable treatment options,” said Anne Kerber, senior vice president, head of development, Hematology, Oncology and Cell Therapy, Bristol Myers Squibb.
“From the potential of golcadomide to offer meaningful benefit in aggressive B-cell and follicular lymphomas, to the innovative mechanism of our BCL6 ligand-directed degrader, BMS-986458, and the proven, long-term efficacy of Breyanzi – these collective results underscore our dedication to pioneering therapies that make a real difference for patients.”
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas.
“The updated data for our BCL6-targeting ligand-directed degrader reinforce the promise of ligand-directed degradation as a novel approach for patients with relapsed or refractory non-Hodgkin lymphoma,” said Michael Pourdehnad, senior vice president, head of early clinical development, Hematology, Oncology and Cell Therapy, Bristol Myers Squibb.
“Seeing strong antitumor activity and meaningful responses, even in heavily pre-treated populations, underscores the potential of this mechanism to address critical unmet needs and advance the standard of care.”
Long-term follow-up from the TRANSFORM and TRANSCEND FL studies confirmed that a single infusion of Breyanzi provides deep, durable responses.
“Results from the TRANSFORM and TRANSCEND FL trials are a remarkable display of the treatment Breyanzi can provide for patients living with certain B-cell lymphomas, offering improved outcomes and consistent safety profile,” said Lynelle B. Hoch, president, Cell Therapy Organization, Bristol Myers Squibb.
“These trial results are reinforced by what we’ve seen in the real world – cell therapy continues to revolutionize the treatment of certain types of blood cancer with deep and durable responses, further inspiring us at BMS to continue driving this modality forward for patients.”
